Presentation by Dr Zsuzsanna Jakab, WHO Regional Director for Europe at the South-eastern Europe Health Ministerial Meeting on Immunization in Podgorica, Montenegro, 20 February 2018
Immunization is a core component of the human right to
health and an individual, community and government responsibility. Protected from the threat of vaccine –preventable diseases, immunized children have the opportunity to thrive and a better chance of realizing their full potential.
Boosting Uganda’s Investments in Livestock Development (2019-2023): Introduci...ILRI
Presented by Dan Tumusiime (MAAIF), Bernard Bett (ILRI), Emily Ouma (ILRI), Samuel Oyola (ILRI), Rosemary Sang (KEMRI), Cornelia Silaghi (FLI), Martin Groschup (FLI), Martin Barasa (VSF-G), Ard Nijhof (FUB) and Cristian Raileanu (FLI) at the #BuildUganda Stakeholder Meeting, Kampala, Uganda, 7 June 2019
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
Overcoming Unmet Needs in Infectious DiseaseCovance
Overcoming Unmet Needs In Infectious Disease Optimize your antibiotic trials with an experienced and trusted partner Each year approximately two million people in the U.S. alone become infected with multi-drug-resistant bacteria and at least 23,000 of these die as a direct result of these infections. There is an urgent need to bring new antibiotics to the market, yet the pipeline for new antibiotics has dwindled.
Immunization is a core component of the human right to
health and an individual, community and government responsibility. Protected from the threat of vaccine –preventable diseases, immunized children have the opportunity to thrive and a better chance of realizing their full potential.
Boosting Uganda’s Investments in Livestock Development (2019-2023): Introduci...ILRI
Presented by Dan Tumusiime (MAAIF), Bernard Bett (ILRI), Emily Ouma (ILRI), Samuel Oyola (ILRI), Rosemary Sang (KEMRI), Cornelia Silaghi (FLI), Martin Groschup (FLI), Martin Barasa (VSF-G), Ard Nijhof (FUB) and Cristian Raileanu (FLI) at the #BuildUganda Stakeholder Meeting, Kampala, Uganda, 7 June 2019
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
Overcoming Unmet Needs in Infectious DiseaseCovance
Overcoming Unmet Needs In Infectious Disease Optimize your antibiotic trials with an experienced and trusted partner Each year approximately two million people in the U.S. alone become infected with multi-drug-resistant bacteria and at least 23,000 of these die as a direct result of these infections. There is an urgent need to bring new antibiotics to the market, yet the pipeline for new antibiotics has dwindled.
Brazzaville – COVID-19 has had a catastrophic impact on lives and livelihoods. But it has also spurred impactful scientific research that gave the world a vaccine in record time and thrust genomic sequencing at the centre of pandemic response.
Presentation at the EU session "Elimination of hepatitis B and C in the EU: challenges and opportunities", at the International Liver Congress (ILC) 2017, Amsterdam.
Presenter: Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
From 10–11 December, the global health community and leaders are meeting in Abu Dhabi to review progress midway through Gavi’s 2016–2020 investment period.
MTR session: This is now…18 years of progress
Dr Berkley reflects on two topics:
- Gavi’s progress vis-à-vis its 2016-2020 promises
- Existing and future Gavi challenges as well as lessons learned.
First presented at the Meningitis Vaccine Project Closure Conference in Addis Ababa in February, Gavi’s CEO Seth Berkley gives a summary of Gavi’s role in reducing the burden of meningitis in Africa.
Africa is getting ready to roll out covidSABC News
Africa marked the move from planning to action in the rollout of COVID-19 vaccines at a World Health Organization (WHO)-hosted African Health Ministers meeting on 17 February, as a rapid vaccine rollout is expected in the wake of the WHO listing of two versions of the AstraZeneca-Oxford COVID-19 vaccine for emergency use.
Presented by Nedret Emiroglu, Deputy Director, Division of Communicable Diseases, Health Security and Environment, WHO/Europe, at the 64th session of the WHO Regional Committee for Europe.
Brazzaville – COVID-19 has had a catastrophic impact on lives and livelihoods. But it has also spurred impactful scientific research that gave the world a vaccine in record time and thrust genomic sequencing at the centre of pandemic response.
Presentation at the EU session "Elimination of hepatitis B and C in the EU: challenges and opportunities", at the International Liver Congress (ILC) 2017, Amsterdam.
Presenter: Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
From 10–11 December, the global health community and leaders are meeting in Abu Dhabi to review progress midway through Gavi’s 2016–2020 investment period.
MTR session: This is now…18 years of progress
Dr Berkley reflects on two topics:
- Gavi’s progress vis-à-vis its 2016-2020 promises
- Existing and future Gavi challenges as well as lessons learned.
First presented at the Meningitis Vaccine Project Closure Conference in Addis Ababa in February, Gavi’s CEO Seth Berkley gives a summary of Gavi’s role in reducing the burden of meningitis in Africa.
Africa is getting ready to roll out covidSABC News
Africa marked the move from planning to action in the rollout of COVID-19 vaccines at a World Health Organization (WHO)-hosted African Health Ministers meeting on 17 February, as a rapid vaccine rollout is expected in the wake of the WHO listing of two versions of the AstraZeneca-Oxford COVID-19 vaccine for emergency use.
Presented by Nedret Emiroglu, Deputy Director, Division of Communicable Diseases, Health Security and Environment, WHO/Europe, at the 64th session of the WHO Regional Committee for Europe.
Gavi’s CEO Dr Seth Berkley presents an overview of the Vaccine Alliance’s achievements to the Board on 22 June 2016. Topics include results and challenges in the 2011-2015 period, early progress in implementing the 2016-2020 strategy and the role of immunisation on the global agenda.
PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED.
October 28, 2018
This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.
Presentation delivered by Dr Nadia Teleb, Regional Adviser, Vaccine Preventable Diseases at the 62nd Session of the WHO Regional Committee for the Eastern Mediterranean
A recent Presentation at National Annual Review Meeting of Core Group Polio Project (CGPP) -USAID funded project, ADRA India: implementing agency with technical support from CORE Secretariat
The PPT gives overview of PEI, global updates on PEI, Polio end game strategy and eradication timelines, polio legacy and link with Health Systems strengthening and relevant health programes etc. The PPT was presented at National Annual Review Meeting held for 2 days in Mussoorie for Core Group of Polio Project (CGPP) -a USAID funded polio eradication initiatives. ADRA India is one of the lead implementing agency for CGPP since 2004 and it has worked for nearly 15 years in polio across states in India.
Presented by H. Nakatani, Assistant Director-General, HIV, TB, Malaria and Neglected Tropical Diseases, WHO, at the 64th session of the WHO Regional Committee for Europe.
Unicef o'connell equity and vaccine supply 5_sep13Rosella Anstine
Similar to Presentation - European Vaccine Action Plan 2015–2020: opportunities and threats, and potential for joint action in south-eastern Europe (20)
Reported measles cases for the period November 2020—October 2021 (data as of 02 December 2021).A monthly summary of the epidemiological data on selected vaccine-preventable diseases in the WHO European Region
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Presentation - European Vaccine Action Plan 2015–2020: opportunities and threats, and potential for joint action in south-eastern Europe
1. European Vaccine Action Plan 2015–2020:
opportunities and threats, and potential for joint
action in south-eastern Europe
South-eastern Europe Health Ministerial Meeting on Immunization
Podgorica, Montenegro, 20 February 2018
Dr Zsuzsanna Jakab
WHO Regional Director for Europe
2. Outline of presentation
• How far we have come
• Unfinished business
• Future prospects and opportunities
2
5. Steady progress towards
measles and rubella elimination goal
0
10
20
30
40
50
2013 2014 2015 2016
0
10
20
30
40
50
2013 2014 2015 2016
#ofMemberStates
#ofMemberStates
Member States that interrupted endemic measles
transmission ≥12 months
Member States that interrupted endemic rubella
transmission ≥12 months
Data source: 2017 meeting report of the European Regional Verification Commission for Measles and Rubella Elimination Note: Verification process not initiated in 2 Member states
79% of Member
States achieved
interruption
70% of Member
States achieved
interruption
Additional member states verified to have interrupted measles transmission for
the year
Additional member states verified to have interrupted rubella transmission for
the year
6. 6
Meet vaccination
coverage targets
Make evidence-based decisions
to introduce new vaccines
Achieve financial
sustainability
Immunization
systems-related goals
Stalled
On
track
On
track
By the end of 2016
7. Regional coverage with diphtheria,
tetanus and pertussis (DTP3) vaccine has
decreased by 4% from 2013
7
96
95
94
95
96 96
93 93
92
70
75
80
85
90
95
100
2008 2009 2010 2011 2012 2013 2014 2015 2016
DTP3 coverage, WHO European Region, 2008–2016
EUR DTP3 coverage
EVAP envisions that >90% of the
districts in the Region should
attain DTP3 coverage of ≥95%.
In 2016, of all the districts:
• only 85% had ≥95% coverage;
• 7% had <80% coverage.
Subnational coverage inequities
exist in the WHO European
Region
8. Infants and children were still missing primary vaccination in 2016
8
Infants missing any DTP
vaccination in the Region,
2016
Ukraine included Ukraine excluded
1 in 21 infants
1 in 45 infants
Children missing first dose of
measles-containing vaccine
(MCV1) in the Region, 2016
Ukraine included Ukraine excluded
1 in 15 infants 1 in 22 infants
Data source: WHO/UNICEF
JRF 2016 data
9. 9
Meet vaccination
coverage targets
Make evidence-based decisions
to introduce new vaccines
Achieve financial
sustainability
Immunization
systems-related goals
Stalled
On
track
On
track
By the end of 2016
10. Countries taking advantage of health gains offered by
new and underutilized vaccines
• Countries are introducing new vaccines
based on NITAG recommendations.
• By the end of 2016:
– 40 Member States had introduced
pneumococcal conjugate vaccine (PCV)
– 32 Member States had introduced human
papillomavirus (HPV) vaccine
– 18 Member States had initiated universal
immunization with rotavirus vaccine
• Three middle-income countries are set
to introduce the HPV vaccine with Gavi
support in 2017.
10
MIC=middle-income countries
MS = Member States
30
35
40
45
50
2014 2015 2016 2017
Figure: Member States with established national
immunization technical advisory group (NITAG)
#ofMemberStates
12. 0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Number of measles cases in the Region, 2007–2017*
Data source: WHO/Europe centralized information system for infectious diseases, extracted 2 February 2018
12
France
19 997 Ukraine
14 079
Kyrgyzstan
18 097Georgia
11 060
2016: 5273 cases
in 34 countries
Bulgaria
24 410
* Data for 2017 is preliminary
2017: 21 315 cases
in 42 countries
Romania
5562
Italy
5006
Ukraine
4767
Measles deaths: 35 (2017*), 13 (2016)
13. a According to 2015 gross national income (World Bank)
b MCV1 = first dose of measles-containing vaccine
Middle-income countries without Gavi support have highest
number of unvaccinated children in the Region
Income level
categorya
Average no. of
antigens
accommodated
/country
Average no.
of new
vaccines
introduced/
country
DTP3 coverage
(population-
weighted
average)
Unvaccinated infants (DTP3) MCV1b
coverage
(population-
weighted
average)
% of Region # of infants
High-income
countries (n=33)
12.5 2.0 96.5% 24.7% 182 250 94.2%
Middle-income
countries (no
Gavi support)
(n=13)
10.4 0.5 88.7% 70.2% 518,850 91.8%
Middle-income
countries (Gavi
support) (n=7)
13.0 2.6 97.3% 5.1% 37 270 97.9%
Regional average
or total #
11.9 1.6 93.4% 738 370 93.6%
13
Data source: WHO/UNICEF Joint Reporting Form, 2015
14. Challenges faced by middle-income countries
• Lack of adequate financial commitment to immunization due to
competing priorities
– This is exacerbated by noneligibility for external funding (for example, from the Gavi
Alliance).
• Difficulty in accessing vaccines at affordable and optimum prices,
including due to global supply shortages
– This also includes delays in procurement, which relies on domestic financial resources.
• Difficulty making evidence-informed decisions, introducing new
vaccines and sustaining the performance of current programmes
• Anti-vaccine sentiment and vaccine hesitancy affecting uptake
14
15. Securing access to affordable vaccine supply in countries of south-
eastern Europe (SEE) for measles-mumps-rubella (MMR), first dose
15
$0.00
$2.00
$4.00
$6.00
$8.00
2013 2014 2015 2016
UMIC40
HIC77
LMIC187
UMIC245
UMIC190
$12.63
$7.20
$7.17
$4.16
$3.97
$2.81
$1.80
$1.32
$0.69
$0.23
-$0.80
-$7.91
-$10.00 -$5.00 $0.00 $5.00 $10.00 $15.00
PCV 1-dose
DTaP-Hib-IPV
Rabies 1-dose
HepB (ped) 1-dose
HepB )adult) 1-dose
IPV 1-dose
Influenza (adult) 1-dose
bOPV1.3 20-dose
MMR 1-dose
BCG 10-dose
DTaP-IPV 1-dose
DTaP-HepB-Hib-IPV
Extra price paid by SEE country group MMR price paid by individual countries
17. Collaborative areas
• Pricing divergence, joint/pooled procurement
• Vaccine demand and acceptance
• Sustained financing and resource mobilization
• Evidence-based decision-making
• Equitable extension of immunization
17
18. The way forward – proposed action
• Voice commitment and set an
ambitious agenda
• Collectively safeguard the
health gains made
• Engage in roadmap
development and goal-setting
• Lead – as ministries – in assuring
these goals are met
18
19. For further information: euvaccine@who.int
Twitter: @WHO_Europe_VPI Facebook: https://www.facebook.com/WHOEurope
19
Vaccination – we must not take the
benefits for granted
Joint statement by Dr Zsuzsanna Jakab, WHO Regional Director for Europe,
and Dr Vytenis Andriukaitis, Commissioner for Health and Food Safety,
European Commission
Thank you
Editor's Notes
I will be considering the progress of the region against the goals and objectives of the European Vaccine Action Plan.
Reflecting on the challenges we are yet to overcome and prompting us to think about the future opportunities and the potential for collaboration.
I would like to encourage us to think how we can fully realize the full potential of the European Vaccine Action Plan and go a step further in setting an ambitious course to get your countries across the line.
SLIDE CHANGE
After a rigorous round of consultations with regional stakeholders, the European Vaccine Action Plan was endorsed at the Regional Committee in September 2014.
The Plan represents a regional adaptation of the Global Vaccine Action Plan, harmonized with Health 2020, and tuned to the European Regional context, along with a detailed monitoring and evaluation plan. That framework enables us to take stock of progress in the Region at the mid-point in 2018. At the Regional Committee in Rome in September this year, the mid-term evaluation will be presented and thereafter disseminated.
The following slides depict the progress made and the particular challenges that affect your countries.
SLIDE CHANGE
Let us first look at the 3 disease-specific goals of the European Vaccine Action Plan.
We have enjoyed a regional polio-free status since 2002. The region has seen this status threatened with circulation detected in Tajikistan, Israel and Ukraine over the past decade, but thanks to a concerted effort and the wealth of work and investment towards strengthening our preparedness and improving the sensitivity of surveillance these threats were contained. Such investment and political commitment will be crucial as we keep on track to contain all polioviruses in secure facilities at a critical moment in the global eradication of this dreaded disease.
In 2015 the Regional Committee endorsed a viral hepatitis action plan for the Region. Hepatitis b vaccination goals and incidence goals were included and in 2016 a hepatitis b verification committee was established to measure our progress against this goal. In this sense, we are on track.
However, we in the Region missed the 2015 measles and rubella elimination goal despite tremendous progress that has been made by our Member States over recent years.
SLIDE CHANGE
The number of countries that have interrupted measles since 2013 has doubled and progress against rubella elimination is also very promising. But we need to keep this momentum up and as many of the countries with us today are aware, measles outbreaks are ongoing in some your countries, indicating immunization programme shortcomings and affecting susceptible pockets of population not protected from this dangerous disease.
Dr John Simpson, member of the Regional Verification Commission for measles and rubella elimination, will highlight, at lunch, the synergies between a well functioning health system, sustaining measles - rubella elimination, and health security.
SLIDE CHANGE
In terms of system related goals we are falling short as a region to meet vaccination coverage targets.
SLIDE CHANGE
This is an alarming picture. Regional diphtheria, tetanus and pertussis vaccination coverage has decreased in the recent years to less than 95%. In our region, 14 countries in 2013 while 22 countries in 2016 achieved less than 95% DTP3 coverage, falling short of the vaccination target outlined in the European Vaccine Action Plan. This, despite a resurgence of both diphtheria and pertussis in the region since 2014. National coverage masks sub-national pockets of much lower vaccination coverage – with 7% of our European districts with lower than 80% coverage – failing to afford communities the herd-immunity they could benefit from. The decline of vaccination coverage in the Region is concerning and it is uneven.
SLIDE CHANGE
With a population of 47 million Ukraine’s very low immunization rates at national and oblast levels, significantly affects the overall status of the Region. Ukraine is not represented here today as we have a dedicated immunization plan that is being implemented with our key partners (some of them represented here today in UNICEF and US CDC) to assist the Ministry recover and improve the delivery of the immunization programme in that country.
After Ukraine, some of the most concerning coverage of immunization programmes are in your countries, hence this initiative today and the need for a positive outlook and collective effort amongst us.
SLIDE CHANGE
In terms of system related goals we are falling short as a region to meet vaccination coverage targets.
SLIDE CHANGE
National Immunization Technical Advisory Groups (NITAGs) are established in 45 countries – on track towards the European Vaccine Action Plan goal and presenting every Member State with a National Immunization Technical Advisory Group to make evidence-informed decisions for new vaccine introduction, taking into account disease burden and cost-effectiveness. In some of the countries represented here today, decisions you are currently taking to introduce HPV, pneumococcal vaccine and rotavirus vaccine will be considerably aided by these groups.
SLIDE CHANGE
We would not be here unless there were challenges that continue to elude us.
SLIDE CHANGE
Huge reductions in disease burden prompted the Region to set an elimination goal for measles and rubella. Following the lowest number of cases in history in 2016, 2017 has again seen a set-back. When this happens it is critical that we take adequate measures to contain the outbreak as soon as possible and consider how we could enforce our commitment. Bulgaria and Romania have experienced large scale outbreaks and many countries in Southeastern Europe are currently suffering, including Serbia – with over 3000 reported cases. We need to actively take control and collectively respond to this. Particularly in this sub-region.
SLIDE CHANGE
Middle-income countries without Gavi support, of which 8 are with us today, represent 38% of the total population in the Region.
The number of vaccines on their programmes are lowest,
the coverage of DTP and measles containing vaccines is lowest,
the percentage of unvaccinated infants is highest in these countries
Additionally,
55% of the total measles cases in 2016 were from these countries
SLIDE CHANGE
Many of your challenges are shared and specific to this context:
These challenges include:
Lack of adequate financial commitment to immunization due to competing priorities
Difficulty in accessing vaccines at affordable and optimum prices
Supply shortage and procurement delays are affecting your programmes
and anti-vaccine sentiment and vaccine hesitancy are affecting uptake
This is not a helpless situation. We would like this event to serve as a catalyst to develop a roadmap for you to overcome these challenges, bring donors to the table to support the partners in providing you with amplified technical assistance, coordinated across the sub-region, striving together towards common goals. The topics chosen for the discussion sessions today highlight these challenges and what we are going to do about them.
SLIDE CHANGE
Collectively, the countries represented in the room here today, pay a higher price for most vaccines, as compared to other middle income countries. The extra price paid reached 12.6 dollars per pneumococcal vaccine.
Additionally, the price you pay as individual countries shows large variations revealing potential inefficiencies and room for improvement.
Collaboration, transparency and joint strategic work on addressing key bottlenecks (from product choice to regulations, budgeting and procurement procedures) is the only approach that will alleviate these two issues.
We have all the ingredients to set a new course for the sub-region:
We have a strong and active sub-regional SEEHN network,
We have an enabling policy environment: with Health 2020 and the European Vaccine Action Plan to draw upon
We have collective commitment to progress against EVAP goals
We have the necessary collaborative spirit and we
Recognize that shared threats are best tackled through joint action.
CHANGE SLIDE
I actively encourage us to set a new set of goals for this sub-region. Recognizing your unique environment and situation. Goals that include:
Pricing divergence and exploring joint/pooled procurement
Driving and maintaining vaccine demand and acceptance
Securing sustained financing and resource mobilization
Establishing bodies that will assure that evidence-based decision are made regarding our programmes,
And, equitably extending the benefits of vaccination so that everyone has access to inclusive immunization services.
Ultimately, we need to enhance sub-regional cooperation in immunization in Southeastern Europe through support of national immunization investments in the areas where they can show an impact on overall health status and are associated with improved investment opportunities that contribute to growth. Dr Thomas Cherian will highlight, at lunch, the full potential of immunization with regard to the SDGs, to health and beyond, including economic growth, employment and education.
Ownership and political commitment will be key to success; and that’s where we start today.
I urge you to support the initiative to develop a sub-regional roadmap and to commit to engaging your immunization programmes and ministries in development of the Roadmap. The clearest signal you can give is your initial affirmation of the Statement of Intent you have received and which we will invite you to endorse later today. I sincerely feel with this commitment of yours to offer the full potential of immunization to the population in this sub-region, each one of you are contributing in-turn to the laid down sustainable development goals we all have committed to.
I would like to highlight this initiative at the Regional Committee in September during the immunization session as an excellent example of how true political commitment is voiced, translated into action and tailored to specific challenges that can only be overcome through collaboration and partnership.
I applaud you for your engagement and thank you for your attention.
CHANGE SLIDE